Business Wire

CA-DRISHTI-TECHNOLOGIES

24.3.2022 11:02:14 CET | Business Wire | Press release

Share
HELLA Improves Cycle Time, Sees Return on Investment in Under Six Months With Drishti

Drishti Technologies, Inc. (Drishti), whose AI-powered manufacturing technology uses video analytics, data and insights to bring significant benefits to manufacturers and their employees, and HELLA (FRA:HLE) a tier-one automotive supplier, today announced the latest in a joint effort to further increase operational efficiency with a second successful combined project in Dhankot, India. HELLA is an internationally positioned automotive supplier globally recognized for its lean practices and is committed to investing in the latest technologies to drive human productivity and improve manufacturing outcomes.

With Drishti cameras and streaming video analysis enabled on one of HELLA’s sensor product lines, the HELLA team made a series of previously concealed discoveries. First, the massive volume of cycle time data available from Drishti quickly revealed slowdowns in stations that were not originally the focus of improvement efforts. Second, by watching video footage from the identified station, the team understood that the physical station configuration was slowing down the line associates.

In fact, the station setup was causing ergonomic concerns. Because the line associate was reaching with his right arm across to the left side of the station, each cycle required a twisting motion that led to fatigue.

“Because our focus had been on the station we thought was the bottleneck, we had overlooked this potential for slowdowns and fatigue,” said Ram Singh Khangarote, operational excellence and operation product manager, HELLA Dhankot. “Within a few minutes of viewing the video footage from Drishti, our team had ideas to reconfigure the station to make it more comfortable for the line associates, and shortening every cycle time. And most importantly, our line associates are healthier, happier and more productive.”

Finally, with Drishti, because the team in Dhankot learned the true cause of line slowdowns, they were able to improve line balancing. The Drishti investment paid for itself in less than six months.

“This is the second instance of finding significant improvement opportunities using Drishti. In 2020, we reduced cycle times in our Guanajuato, Mexico plant . Now we’re seeing value in Dhankot, as well,” said Huri Mendoza, head of operational excellence, HELLA. “Drishti’s technology perfectly complements our goal of achieving operational excellence by augmenting our extremely capable workforce and empowering them with the tools they need to perform their jobs even better.”

The Dhankot plant deployment is one of several ongoing collaborations between HELLA and Drishti. Drishti streams video at every station on a line, then uses proprietary AI networks to translate video streams into data, a technique called action recognition. The line-level data on cycles and actions helps manufacturers improve productivity and quality while improving standardized work adherence.

“Drishti’s action recognition technology provides manufacturers with a clear competitive edge, as they can see improvement opportunities on assembly lines that are otherwise hidden,” said Gary Jackson, CEO, Drishti. “HELLA’s success with Drishti is in line with what we’re seeing across the automotive industry, as well as in other verticals like electronics and medical devices. The future of automated video analysis, which creates insights on people at work, runs through Drishti.”

About Drishti

Drishti’s AI-powered video analytics technology augments human workers and provides visibility and insights that transform the pace and impact of manual assembly line improvement. Manufacturers use Drishti to anchor true digital transformation, driving sweeping improvements in quality costs, efficiency gains & time-to-proficiency for line associate training. And line associates rely on Drishti to be more consistent and efficient, becoming even more valuable on the factory floor. Drishti has been recognized as a World Economic Forum Technology Pioneer and a Forbes AI 50 company, among others. For more information, visit drishti.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye